Key result
The editorial discusses the economic, legal, and programmatic challenges of adopting drug-eluting stents and announces the formation of a task force to provide guidance on these non-scientific aspects.
Answers are grounded in this paper and cite their sources.
An editorial discussing the economic, legal, and programmatic challenges of adopting drug-eluting stents and the formation of a SCAI task force to provide guidance.
I have graphed this progression and its associated cost in an admittedly non-rigorous way, but I believe a fairly accurate one (Fig 1). I have corrected the device costs for inflation and expressed them in 2002 US dollars. As you can see, for a progressive improvement in restenosis, DES come at a price increase which appears in line with prior advances. One could argue that the development costs or the complexity of these new stents does not warrant such an increase, but I believe that once a competitive device hits the market, traditional market forces will mediate the cost issues. In the meantime, although formal cost-effectiveness evaluations of the SIRIUS trial data [11] suggest that “society” is willing to pay the additional cost to achieve lower TLR rates, it is widely expected that significant hospital losses will occur. There is no mechanism for redistributing the societal gains from reduced repeat procedures back to the hospital that originally bought the DES. This reality is still present in many countries outside the United States despite DES marketing approval of greater than one year. In these countries, adoption generally remains less than 15%. Estimates of restenosis rates and costs (2002 US$) for various devices in single vessel disease near the time of their introduction. DCA: directional coronary atherectomy, DES: drug-eluting stent. I recently polled several US colleagues as to how they expected to deal with the use of DES in their institutions. I was distressed by the variety of plans ranging from universal use (for some due to a belief that DES would be best in all lesions; for some out of fear of litigation), to a very rigid scoring system based on anticipated restenosis risk. Some in the mid ground planned to use one DES per case with bare metal stents for the additional vessel/lesions (this seemed to be the most fiscally sound, capturing the added reimbursement while limiting the outlay). I was distressed because the planned use had little to do with scientific data, but rather in many cases was driven by financial considerations or fear of litigation. This only confirmed the SCAI poll taken last October and reported in the Spring Newsletter [12]. In the Society's DES position statement [13], we suggested the formation of a task force to address these issues. During the annual scientific sessions in Boston, we convened the first task force meeting. Many different interest groups were represented, including the American College of Cardiology, American Heart Association, Council of Cardiovascular Organizations, three device manufacturers, payers, hospital administrators and health care economists. We had a very congenial meeting and agreed to work on three areas with the intent of providing some guidance to interventionalists during these DES “growing pains”. The first area was to explore the economic impact of DES from four different perspectives: the patient, the hospital, the payers and the health care system. With SCAI leadership, an analysis of this complex problem will be developed in the near future. The second area of focus for the task force is to look at the impact of DES on health care delivery. Due to the economics, supply issues and differing practice patterns, there may be variability in access to these devices. Additionally, there may be dramatic programmatic changes; for example, if the proposed shift from coronary bypass surgery to multivessel DES implantation occurs at a rate of 10–15%/year, some lower volume surgery programs may become non-viable. For example, in Ohio, where an open-heart program is required on-site to do angioplasty, such reductions may lead to closure of interventional programs in an odd paradox of self-inflicted regulatory suicide. Innovative new programs that maximize appropriate delivery of the entire spectrum of cardiac revascularization will need to be developed. The final area of discussion for the task force is the medical-legal implications surrounding DES use. As noted in the SCAI survey last fall, the majority of US-based interventionalists are concerned about the legal ramifications of using DES or bare metal stents. The task force will explore the reality of these concerns and offer some guidance in this area. In summary, the charge of the DES Task Force is to provide up-to-date guidance on the non-scientific aspects of DES implementation. It is our hope that this guidance will be useful in empowering the interventionalists to practice optimal medicine without fear of economic, legal or programmatic consequences. At the Boston meeting, I also noted an interesting presentation. Sharifi, et. al. reported a new interventional therapy that, in the first-in-man series, resulted in a TLR rate of 0% at 14 months [14]. Sounds reminiscent of the original DES data. In this series, however, there were no new devices, only application of an old concept: hyperbaric oxygen therapy (HOT). Of course, the TLR will unlikely remain 0% as more patients are studied, but it put in perspective what we do and how we evaluate our procedures. Ultimately, we need new devices (e.g. stents), we need new pharmacology (e.g. sirolimus), we need adjunctive techniques (e.g. FFR, IVUS), and we need thinking “outside the box” (HOT). We are in exciting times; restenosis is now in the single digits. The treatment of coronary disease in some ways has never been easier, but in other ways, never so complex. We should embrace the science of DES, but be careful not to lose sight of the other exciting advances of the past 15 years. And certainly, we cannot rest in our pursuit of even greater accomplishments, while always keeping the optimal care of our patients paramount. I will keep you informed of the task force findings as they become available. I trust they will offer some guidance for us all.
No takes yet. Share an insight, caveat, or question.
John McB. Hodgson (2003) conducted an editorial in Coronary disease. Drug-eluting stents vs. Bare metal stents was evaluated. The editorial discusses the economic, legal, and programmatic challenges of adopting drug-eluting stents and announces the formation of a task force to provide guidance on these non-scientific aspects.
Synapse has enriched 10 related papers. Consider them for comparative context: